249 completed. 249 Phase 2, 73 Phase 1, 7 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 249 | Completed 249 |
| Phase 1 | 73 | Completed 73 |
| Phase 3 | 7 | Completed 7 |
Follow Hematologic Neoplasms: new trials by email Literature Review of Hematologic Neoplasms trials Research Report on Hematologic Neoplasms
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety and Efficacy of CD123-targeted CAR-NK for Relapsed/Refractory Acute Myeloid Leukemia or Blastic Plasmacytoid Dendritic Cell Neoplasm CD123 targeted CAR-NK cells - Acute Myeloid Leukemia, Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) | Phase 1 / Phase 2 | Completed | Chongqing Precision Biotech Co., Ltd | 5 | 2024-03-28 | 2026-08-05 |
| Study of AZD9829 in CD123+ Hematological Malignancies AZD9829 - Hematological Malignancies | Phase 1 / Phase 2 | Completed | AstraZeneca | 56 | 2024-01-31 | 2026-07-01 |
| A Study of Bomedemstat (IMG-7289/MK-3543) in Participants With Polycythemia Vera (IMG-7289-CTP-203/MK-3543-004) Bomedemstat - Polycythemia Vera | Phase 2 | Completed | Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA) | 20 | 2023-09-07 | 2026-05-07 |
| Study of VIP152, Venetoclax, and Prednisone (VVIP) in Relapsed/Refractory Lymphoid Malignancies Vysis LSI MYC Break Apart Rearrangement Probe Kit, Venetoclax, VIP152 - Lymphoma, Non-Hodgkin Lymphoma | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 8 | 2023-04-05 | 2026-02-23 |
| CD7 CAR-T for Patients With r/r CD7+ Hematologic Malignancies Anti-CD7 CAR-T - Hematological Malignancies | Phase 2 | Completed | Institute of Hematology & Blood Diseases Hospital, China | 14 | 2022-09-07 | 2025-03-13 |
| A Study to Evaluate Sapablursen (Formerly ISIS 702843, IONIS-TMPRSS6-LRx) in Patients With Polycythemia Vera sapablursen - Phlebotomy Dependent Polycythemia Vera | Phase 2 | Completed | Ionis Pharmaceuticals, Inc. | 50 | 2021-12-30 | 2026-07-09 |
| A Study of Pembrolizumab/Vibostolimab (MK-7684A) in Relapsed/Refractory Hematological Malignancies (MK-7684A-004, KEYVIBE-004) Pembrolizumab/vibostolimab coformulation - Hematological Malignancies | Phase 2 | Completed | Merck Sharp & Dohme LLC | 192 | 2021-09-28 | 2026-02-19 |
| PHASE II SINGLE-CENTER, RANDOMIZED, OPEN-LABEL, PROSPECTIVE, STUDY TO DETERMINE THE IMPACT OF SERIAL PROCALCITONIN Imipenem/Cilastatin/Relebactam, Cefepime, Meropenem - Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm | Phase 2 | Completed | M.D. Anderson Cancer Center | 100 | 2021-09-14 | 2026-04-06 |
| To Assess the Safety, Tolerability and Efficacy of Itacitinib Immediate Release Tablets in Participants With Primary or Secondary Myelofibrosis Who Have Received Prior Ruxolitinib and/or Fedratinib Monotherapy (LIMBER-213) itacitinib - Myelofibrosis, Polycythemia Vera | Phase 2 | Completed | Incyte Corporation | 4 | 2021-07-12 | 2025-09-02 |
| Front Line Ibrutinib Without Corticosteroids for Newly Diagnosed Chronic Graft-versus-Host Disease Ibrutinib, ECG, PFT's - Chronic GVHD | Phase 2 | Completed | National Cancer Institute (NCI) | 10 | 2021-05-10 | 2026-01-23 |
| A Trial of the Safety and Immunogenicity of the COVID-19 Vaccine (mRNA-1273) in Participants With Hematologic Malignancies and Various Regimens of Immunosuppression, and in Participants With Solid Tumors on PD1/PDL1 Inhibitor Therapy Messenger ribonucleic acid (mRNA)-1273 Vaccine, Messenger ribonucleic acid (mRNA)-1273 Vaccine Booster, ECG - Solid Tumor Malignancy, Hematologic Malignancy | Phase 2 | Completed | National Cancer Institute (NCI) | 19 | 2021-04-28 | 2024-08-27 |
| Risk-adapted Donor Lymphocyte Infusion After Allo-HSCT in Children With Hematologic Malignancy Prophylactic Donor lymphocytes infusions, Preventive Donor lymphocytes infusions - Hematologic Malignancy | Phase 1 / Phase 2 | Completed | St. Petersburg State Pavlov Medical University | 50 | 2021-04-01 | 2024-06-25 |
| A Study of Teclistamab in Japanese Participants With Relapsed or Refractory Multiple Myeloma Teclistamab - Hematologic Malignancies | Phase 1 / Phase 2 | Completed | Janssen Pharmaceutical K.K. | 40 | 2021-02-22 | 2026-06-05 |
| Assessing Feasibility of Thromboprophylaxis With Apixaban in JAK2-positive Myeloproliferative Neoplasm Patients Apixaban 2.5 MG Oral Tablet [ELIQUIS], Aspirin 81 mg - Myeloproliferative Neoplasm (MPN), Essential Thrombocythemia (ET) | Phase 2 | Completed | Ottawa Hospital Research Institute | 44 | 2021-02-17 | 2024-05-29 |
| PTG-300 in Patients With Polycythemia Vera and Elevated Hematocrit PTG-300 - Polycythemia Vera | Phase 2 | Completed | Protagonist Therapeutics, Inc. | 20 | 2021-02-02 | 2024-03-18 |
| Leflunomide for the Treatment of Severe COVID-19 in Patients With a Concurrent Malignancy Best Practice, Leflunomide, Placebo Administration - Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm | Phase 1 / Phase 2 | Completed | City of Hope Medical Center | 2 | 2021-01-07 | 2024-07-03 |
| Study of Benralizumab in People With Skin Side Effects Caused by Cancer Therapies Benralizumab - Solid Tumor, Solid Carcinoma | Phase 2 | Completed | Memorial Sloan Kettering Cancer Center | 51 | 2020-09-16 | 2026-06-01 |
| Anakinra for the Reduction of CAR-T Toxicity in Patients With Relapsed or Refractory Large B-cell Lymphoma Anakinra, Axicabtagene Ciloleucel, Cyclophosphamide - Hematopoietic and Lymphoid Cell Neoplasm, Recurrent Diffuse Large B-Cell Lymphoma | Phase 2 | Completed | M.D. Anderson Cancer Center | 22 | 2020-07-27 | 2025-01-28 |
| Tildrakizumab for Prevention of Acute Graft-Versus-Host Disease Tildrakizumab - Hematologic Malignancies | Phase 2 | Completed | Medical College of Wisconsin | 51 | 2020-03-01 | 2025-10-21 |
| Efficacy and Safety of P1101 in Polycythemia Vera Patients for Whom the Standard of Treatment is Difficult to Apply P1101, Low-dose aspirin, Phlebotomy - Polycythemia Vera (PV) | Phase 2 | Completed | PharmaEssentia Japan K.K. | 29 | 2019-12-20 | 2025-09-15 |
Showing 20 of 249. Sign in to see all of them.
Polycythemia Vera (71) · Leukemia, Myeloid, Acute (59) · Primary Myelofibrosis (59) · Leukemia (54) · Multiple Myeloma (52) · Myelodysplastic Syndromes (52) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (49) · Myeloproliferative Disorders (48) · Thrombocythemia, Essential (46) · Hodgkin Disease (38) · Lymphoma (38) · Lymphoma, Non-Hodgkin (37) · Leukemia, Lymphocytic, Chronic, B-Cell (34) · Graft vs Host Disease (26)
Hemic and Lymphatic Diseases (249) · Neoplasms by Site (249) · Hematologic Diseases (238) · Neoplasms (232) · Neoplasms by Histologic Type (126) · Bone Marrow Diseases (118) · Immune System Diseases (117) · Immunoproliferative Disorders (98) · Lymphoproliferative Disorders (97) · Lymphatic Diseases (85) · Hemorrhagic Disorders (82) · Pathological Conditions, Signs and Symptoms (72) · Bone Marrow Neoplasms (71) · Pathologic Processes (71)
Cyclophosphamide (39) · Tacrolimus (35) · fludarabine phosphate (29) · Mycophenolic Acid (28) · Busulfan (27) · Whole-Body Irradiation (25) · fludarabine (22) · Peripheral Blood Stem Cell Transplantation (21) · Methotrexate (19) · Antilymphocyte Serum (17) · Melphalan (15) · Cyclosporine (11) · Stem Cell Transplantation (10) · thymoglobulin (9) · Filgrastim (8)
M.D. Anderson Cancer Center (23) · National Cancer Institute (NCI) (15) · Fred Hutchinson Cancer Center (14) · Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University (11) · Novartis Pharmaceuticals (8) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (5) · Dana-Farber Cancer Institute (4) · H. Lee Moffitt Cancer Center and Research Institute (4) · Stanford University (4) · University of Liege (4) · Bristol-Myers Squibb (3) · Italfarmaco (3) · Kiadis Pharma (3) · Mayo Clinic (3) · Medical College of Wisconsin (3)
United States (183) · Italy (26) · France (22) · United Kingdom (21) · Germany (20) · Canada (17) · Spain (13) · Belgium (12) · Australia (11) · Netherlands (9) · Israel (8) · Poland (8) · China (7) · Denmark (6) · South Korea (6)
Neal Flomenberg, MD (5) · Yves Beguin, MD, PhD (4) · Alessandro Rambaldi, MD (3) · Frederic Baron, MD, PhD (3) · Issa Khouri (3) · Jorge Cortes, MD (3) · Patrick Stiff, MD (3) · Robert Lowsky (3) · Srdan Verstovsek, MD (3) · Usama Gergis, MD (3) · Andrew M Yeager, MD (2) · Ayalew Tefferi, MD (2)
PMID 23065508, PMID 23524640, PMID 32499241, PMID 10204198, PMID 11468154, PMID 16115130, PMID 16192477, PMID 16709929, PMID 16980990, PMID 17162214, PMID 17606446, PMID 18451242, PMID 18650451, PMID 19345145, PMID 19423725, PMID 19462317, PMID 19528536, PMID 19667400, PMID 19713456, PMID 19841031, PMID 20007996, PMID 20107229, PMID 20109568, PMID 20528878, PMID 20650872, PMID 20651074, PMID 20661232, PMID 20685246, PMID 20733120, PMID 20843246, PMID 21868572, PMID 22198152, PMID 22491731, PMID 22718840, PMID 23453583, PMID 23861248, PMID 23890523, PMID 24295572, PMID 24362550, PMID 24566820, PMID 24607552, PMID 24859366, PMID 24903629, PMID 24911148, PMID 25046834, PMID 25047979, PMID 25075128, PMID 25261096, PMID 25267759, PMID 25283774
P01CA018029 (5), P30CA015704 (5), P01CA015396 (3), 2014 (2), P30CA006973 (2), P30CA015083 (2), P30CA016672 (2), U10CA180820 (2), U24CA196172 (2), 2005 (1), 2008 (1), 2015 (1), 2018 (1), 2023 (1), K08HL143189 (1)